Local News
Adults from the area take part in a “game-changing” Alzheimer’s medication trial
By 
Editor
Rochester, New York – A small group of local adults took part in a study for a brand-new Alzheimer’s medication.
Lecanemab, the medication, was evaluated in phase 3 international clinical trial. According to drug producers, a monoclonal antibody treatment for Alzheimer’s disease significantly delayed the rate of cognitive loss compared to a placebo.
This is a significant step towards postponing the disease’s consequences, according to Dr. Anton Porsteinsson, Director of the University of Rochester Alzheimer’s Disease Care.
“What the families say, I want to keep them the way they are now for as long as possible so that we can enjoy the time that we have together and delay the time until they need all of the constant supervision,” said Dr. Porsteinsson.
By the end of March 2023, the trial’s participating companies hope to receive regulatory approval from the United States.
-
Local News2 weeks agoFollowing an ATV accident, a man was rescued from Flint Creek
-
Local News1 week agoReunited Afghan family in Rochester after almost ten years apart
-
Local News2 weeks agoThe New York measure would alter the way that auto warranty service is paid for
-
Local News1 week agoResidents in Rochester are irritated by careless driving
-
Local News1 week agoStrong Hospital has a significant police presence during a search for a man from Livingston County
-
Local News2 weeks agoReactions from RG&E and community supporters to Monroe County’s denial of funding for a public utility study
-
Local News2 weeks agoThe new Senate resolution is ‘encouraging’ for the widow of the Taliban-detained guy from Dansville
-
Local News1 week agoNumerous people walk to bring attention to Black maternal mortality